Introduction {#s0005}
============

Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second leading cause of cancer death in men and women combined in the United States [@bb0005]. CRC is thought to result from the accumulation of genetic alterations, which give cells a survival advantage over surrounding cells. An important genetic change in CRC is mutation of *SMAD4* leading to loss of SMAD4 protein expression. SMAD4 protein expression is lost in approximately 30% to 40% of the CRCs [@bb0010], [@bb0015], [@bb0020] and is associated with metastasis formation and poor response to chemotherapy [@bb0025], [@bb0030], [@bb0035], [@bb0040]. *SMAD4* is the common mediator of the transforming growth factor--β and bone morphogenetic protein pathways and is located on chromosome 18q21. SMAD4 immunohistochemistry correlates very well with the genetic status as is shown in juvenile polyposis [@bb0045]. SMAD4 immunohistochemistry is therefore frequently used to ascertain the SMAD4 status of a tumor. Although the use of SMAD4 immunohistochemistry as a molecular marker has been studied in multiple studies, this has mostly been performed in small cohorts and in different subgroups using different survival endpoints. Most studies report an association between SMAD4 loss and a poor prognosis, but this is not consistent. To our knowledge, there has never been a comprehensive study combining all these results to truly establish the predictive value of SMAD4 immunohistochemistry for clinical use. Therefore, we conducted a meta-analysis to correlate the SMAD4 immunohistochemistry expression with survival outcomes.

Methods {#s0010}
=======

Publication Selection {#s0025}
---------------------

Pubmed and Google Scholar were used to search for potentially relevant literature. The search entry used was ("colorectal OR large intestine" OR "large bowel" OR "colon" OR "colonic" OR "rectal" OR "rectum") AND ("cancer" OR "carcinoma" OR "tumor" OR "tumour" OR "neoplasm" OR "cancers") AND ("SMAD4" OR "DPC4") AND ("marker" OR "signature molecule" OR "molecular marker" OR "markers" OR "biomarkers" OR "biomarker" OR "marker" OR "prognosis" OR "predictive" OR "survival"). Additionally, reference lists of the studies found and of systematic reviews were also checked for potential articles. The search was performed in September 2014.

First, the abstracts were checked for relevance and full articles were retrieved when potentially eligible. To be included in the analysis, studies had to have been performed in resected colorectal carcinomas and immunohistochemistry for SMAD4 had to have been performed. One or more of the following endpoints had to be described: overall survival (OS), disease-free survival (DFS), or cancer-specific survival (CSS). Both univariate and multivariate analyses were taken into account, although separately analyzed. All selected studies were checked according to a 20-point quality control system developed previously ([Table S1](#ec0005){ref-type="supplementary-material"}) [@bb0050], [@bb0055], [@bb0060].

Statistical Analysis {#s0030}
--------------------

Data were extracted by two independent researchers. When not reported, the log hazard ratio (HR) and confidence interval (CI) were extracted using previously published methods [@bb0065], [@bb0070]. The meta-analysis was performed in STATA12 using the *metan* package. Pooled HR and 95% CI were calculated for each endpoint (OS, DFS, and CSS) and presented in a forest plot. An HR \> 1 implies a worse prognosis for SMAD4-negative CRCs. A *P* value of \< .05 was considered significantly different. Heterogeneity was calculated and presented as *X*^2^ and *I*^2^. We chose to perform random effect models based on the fact that the studies differed in size, country, and most importantly in the method of scoring and cutoff values. The log~e~ standard error of the HR and log~e~ HR of each study were plotted in a funnel plot to assess potential publication bias.

Results {#s0015}
=======

Search Results {#s0035}
--------------

The search resulted in 137 studies. On the basis of the abstracts, 19 studies were considered eligible, of which 6 were eventually excluded on the basis of the fact that the HR and CI could not be extracted. The 13 eligible studies consisted of a total of 3800 patients, ranging from 86 to 1381 per study. The main characteristics of the studies can be found in [Table 1](#t0005){ref-type="table"}. We included OS, CSS, and DFS in this study but analyzed the different endpoints separately. We also made a distinction between univariate and multivariate analyses. Five studies only included colon cancer, and the other eight studies included both colon and rectal cancers. Six studies reported that a portion or all of the patients received adjuvant chemotherapy after resection. Three studies did not report the mean or median age and three studies did not report the mean or median follow-up period. Five studies reported CSS, five studies reported DFS, and seven studies reported OS. Eight studies described specifically that only nuclear staining of SMAD4 was considered positive. One study considered both cytoplasmic and nuclear staining as positive and four studies did not describe their scoring methods. All studies used SMAD4 antibodies produced by Santa Cruz Biotechnology Inc (Dallas, TX) except for Li et al. who used an antibody from Zhongshan Biotechnology Inc. All studies except Isaksson-Mettävainio [@bb0120] had dichotomized the scoring. For Isaksson-Mettävainio [@bb0120], we have compared the categories depicted as SMAD4^high^*versus* SMAD4^loss^ and we have not considered the category SMAD4^moderate^. The mean and median positive SMAD4 score is 70.9% and 76.5%, respectively, with a range of 26% to 90.7%.Table 1Studies included in meta-analysisStudyYearCountryStageNo. of PatientsInclusion PeriodABDilutionSiteAge (year)Follow-UpOutcomeCytoplasm NuclearPreserved SMAD4 (%)Adjusted TherapyAlazzouzi [@bb0075]2005FinlandIII861993-1997Santa Cruz Biotechnology Inc1:1000Colon/rectumMean, 70.1At least 6 yearsDFS and OSNA26NoAlhopuro [@bb0025]2005FinlandIII751994-1998Santa Cruz Biotechnology Inc1:1000Colon/rectumMean, 59Mean, 8.7 yearsDFS and OSNA86.7YesIsaksson-Mettävainio [@bb0090]2006SwedenI-III861987-1994Santa Cruz Biotechnology Inc1:50Colon/rectumNANACSSNuclear90.7NoBacman [@bb0085]2007GermanyII-III3051991-2001Santa Cruz Biotechnology Inc1:50ColonMedian, 64Median, 91 monthsCSSNuclear85.6YesMesker [@bb0095]2009NetherlandsI-II1181980-2001Santa Cruz Biotechnology Inc1:400ColonMean, 68.2Up to 25 yearsDFS and OSNuclear76.5NoGulubova [@bb0100]2010BulgaryI-IV1381997-2006Santa Cruz Biotechnology Inc1:50Colon/rectumMedian, 65Median, 37.6 monthsOSNuclear88.4NoLi [@bb0105]2011ChinaI-IV1472003-2004Zhongshan Biotechnology1:150ColonNAUp to 5 yearsDFS and OSNuclear74.1NoBaraniskin [@bb0110]2011GermanyIV190NASanta Cruz Biotechnology Inc1:100Colon/rectumMean, 64.4NAOSNuclear65.8YesAhn [@bb0115]2011South KoreaI-IV4291991-2000Santa Cruz Biotechnology Inc1:200Colon/rectumMean, 57Median, 56 monthsDFSNA47.3YesIsaksson-Mettävainio [@bb0120]2012SwedenI-IV4411995-2003Santa Cruz Biotechnology Inc1:100Colon/rectumNANACSSNuclear80.3YesLampropoulos [@bb0125]2012GreeceI-IV1952005-2006Santa Cruz Biotechnology Inc1:100Colon/rectumMean, 68.6Median, 56 monthsCSSBoth61.5NoRoth [@bb0130]2012SwitzerlandII-III1381NASanta Cruz Biotechnology Inc0.2 mg/mlColonMedian, 60Median, 69 monthsOS and DFSNA78.8YesVoorneveld [@bb0080]2013NetherlandsI-IV2091983-2004Santa Cruz Biotechnology Inc1:400ColonMean, 68.9Median, 65 monthsCSSNuclear60No

Cancer-Specific Survival {#s0040}
------------------------

Three studies included a univariate CSS with a total of 600 patients (range 86-305). The pooled HR is 1.75, which is not significantly different (95% CI: 0.93-3.32; *z*= 1.69; *P*= .09; [Figure 1](#f0005){ref-type="fig"}). Four studies included a multivariate CSS with a total of 931 patients (range 86-441). The pooled HR is 2.17, which is significantly different (95% CI: 1.56-3.01; *z*= 4.65; *P*= .000), indicating that SMAD4 loss is associated with a worse CSS in this pooled multivariate analysis.Figure 1Forest plots of the CSS.

Disease-Free Survival {#s0045}
---------------------

Six studies included a univariate DFS with a total of 2236 patients (range 75-1381), and three studies included a multivariate DFS with a total of 1646 patients (range 118-1381). The pooled HR for the univariate DFS is 2.11 (95% CI: 1.36-3.28; *z*= 3.32; *P*= .001), and the pooled HR for the multivariate DFS is 2.15 (95% CI: 1.56-3.01; *z*= 4.65; *P*= .000), which are both significantly different ([Figure 2](#f0010){ref-type="fig"}). The univariate and the multivariate DFS meta-analyses confirm that SMAD4 loss is associated with a poor DFS.Figure 2Forest plots of the DFS.

Overall Survival {#s0050}
----------------

Seven studies included a univariate OS with a total of 2135 patients (range 75-1381), and four studies included a multivariate OS with a total of 1836 patients (range 118-1381). The pooled HR for the univariate OS is 2.30 (95% CI: 1.41-3.73; *z*= 3.36; *P*= .001), and the pooled HR for the multivariate OS is 2.28 (95% CI: 1.30-4.00; *z*= 2.89; *P*= .004) ([Figure 3](#f0015){ref-type="fig"}). Both the univariate and the multivariate OS meta-analyses showed that SMAD4 loss is associated with a poor OS.Figure 3Forest plots of the OS.

Publication Bias {#s0055}
----------------

The funnel plots for the assessment of potential publication bias show one considerable outlier in the univariate and multivariate OS and the univariate DFS ([Figure 4](#f0020){ref-type="fig"}). Although in the univariate OS this does not result in a significant Egger test, we chose to exclude the outliers in all the meta-analyses and recalculate the pooled HRs. Exclusion of the outlier reduces the pooled HR of the univariate OS to 1.673 (95% CI: 1.42-1.96; *z*= 6.08; *P*= .000). The pooled HR of the multivariate OS is reduced to 1.55 (95% CI: 1.29-1.86; *z*= 4.68; *P*= .000), and the pooled HR of the univariate DFS is 1.6 (95% CI: 1.23-2.08; *z*= 3.53; *P*= .000).Figure 4Funnel plots of all the meta-analyses.

Discussion {#s0020}
==========

Molecular profiling of individual tumors potentially allows a personalized approach to cancer treatment. Estimation of prognosis plays an important role in decisions about treatment, and this is currently almost entirely dependent on histopathologic staging. *SMAD4*, located on chromosome 18q21, has frequently been reported to be a useful prognostic marker. Several studies have reported the prognostic value of SMAD4 expression using immunohistochemistry [@bb0075], [@bb0080], although this has not been entirely consistent [@bb0085]. To our knowledge, this is the first comprehensive meta-analysis of the predictive value of SMAD4 expression using immunohistochemistry.

We included three different endpoints, namely OS, CSS, and DFS, and both univariate and multivariate analyses. All the meta-analyses, except the univariate CSS, showed a significant difference in HR implying that loss of SMAD4 expression as measured by immunohistochemistry is associated with a poor prognosis. Thirteen studies have investigated the prognostic value of SMAD4 loss using different types of endpoints resulting in relative few studies per single endpoint. The analyses of the univariate OS and DFS included the largest numbers of studies (seven each), which make these the most reliable results. To investigate the heterogeneity, *I^2^* was calculated, which was more than 50% in most of the cases, except for the univariate and multivariate analyses of the CSS. Conventionally, when *I^2^* is more than 50% and the distribution is significantly heterogeneous (*P*\< .05), the fixed model cannot be used and the random effects model has to be applied, but prior to conducting the analysis, we had already decided to use the random effects model for all the meta-analyses because of the variation in the methodology of the studies included. One aspect that varies between the studies is the percentage of SMAD4 preservation, which is dependent on the staining and scoring method used. SMAD4 is the common mediator of the bone morphogenetic protein/transforming growth factor--β signaling pathways and complexes with phosphorylated R-SMADs, which then enter the nucleus to modulate gene transcription. Only nuclear localization shows active functional SMAD4. Not all studies used only nuclear staining and four studies did not report what they considered as positive. Another source of heterogeneity is the population that was used in each of the studies. Seven studies included all the stages and the other six included only one or two stages. Six studies included patients that had received chemotherapy, while in seven studies no adjuvant therapy was applied. These differences can affect the outcome of the individual studies and can increase the heterogeneity in the meta-analysis.

Despite the fact that the pooled studies of univariate CSS did not show a significant difference, we conclude, on the basis of the other five meta-analyses all showing statistically significant associations, that immunohistochemical analysis of SMAD4 expression is a useful prognostic marker in colorectal cancer. Immunohistochemistry is a relative easy technique to perform and is readily available in most hospital pathology departments. International recommendations to standardize SMAD4 scoring methodology are required.
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